Apimeds Pharmaceuticals US, Inc (APUS) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
APUS Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Apimeds Pharmaceuticals US, Inc (APUS) trades at a price-to-earnings ratio of -2.7x, with a stock price of $1.47 and trailing twelve-month earnings per share of $-551.47.
Compared to the Healthcare sector median P/E of 22.3x, APUS trades at a 112% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, APUS trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our APUS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
APUS P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $8B | 25.5 | 1.11 | -25% | |
| $2B | 36.3 | 4.85 | +1883%Best | |
| $30B | 22.8 | 0.56Best | +5% | |
| $12B | 28.1 | 0.88 | +21% | |
| $10B | 13.1Lowest | 1.87 | +29% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See APUS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs APUS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare APUS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAPUS — Frequently Asked Questions
Quick answers to the most common questions about buying APUS stock.
Is APUS stock overvalued or undervalued?
APUS current P/E: -2.7x. 5-year average P/E: N/A. Percentile: N/A.
How does APUS's valuation compare to peers?
Apimeds Pharmaceuticals US, Inc P/E of -2.7x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is APUS's PEG ratio?
APUS PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.